Dr Reddy's settles patent litigation with Indivior, Aquestive Therapeutics

Dr Reddys Laboratories on Thursday said it has settled patent litigation with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction.

On June 28, 2022, a US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.

The stipulation of dismissal was filed pursuant to a settlement agreement that the company entered into with Indivior and Aquestive, it added.

“The settlement and dismissal resolve all claims between the parties, including Indiviors and Aquestives claims for patent infringement as well as the companys antitrust counterclaim against Indivior,” Dr Reddys said.

On June 24, Dr Reddys announced that it has entered into a settlement agreement with Indivior Inc and Aquestive Therapeutics as a result of which it will receive payments totalling USD 72 million by March 31, 2024.

The said agreement resolves all claims between the parties relating to the companys generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, it had said. Buprenorphine and naloxone sublingual film medication is used to treat opioid dependence or addiction.

(Except for the headline, this story has not been edited by The Federal staff and is auto-published from a syndicated feed.)